CPT 81479 Reimbursement & Policy Benchmarks

CPT code 81479 designates an unlisted molecular pathology procedure and is used when a molecular or genomic test lacks a specific CPT code. Nationally, this code matters because it captures novel, customized, or otherwise uncoded molecular diagnostic assays that are increasingly used for precision medicine, rare disease evaluation, and complex oncology testing. Payers apply differing policies for coverage and reimbursement of unlisted molecular tests, making coding clarity and documentation critical for claims processing.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of what 81479 represents, the clinical and laboratory contexts in which it is used, and where it typically appears on claims. The publication outlines typical payer considerations, claims documentation expectations, and the kinds of benchmarks and policy updates that affect use of unlisted molecular pathology codes.

This summary equips billing managers, laboratory directors, and policy analysts with a concise orientation to 81479, what stakeholders review when processing unlisted molecular tests, and the areas where payers commonly exercise medical necessity, prior authorization, and clinical evidence review. Data not available in the input for specific payer policies, associated taxonomies, ICD-10 pairings, and detailed reimbursement benchmarks.

Billing Code Overview

CPT code 81479 is an unlisted molecular pathology procedure code used to report a molecular pathology service that does not have a more specific CPT code. This code captures unique or new molecular diagnostic tests when no designated CPT code exists.

Service Type: Molecular pathology / molecular diagnostic testing

Typical Site of Service: Clinical laboratory or outpatient diagnostic laboratory setting, including hospital labs and independent reference laboratories.

If additional detail for associated taxonomies, ICD-10 diagnoses, related codes, or service line is required, Data not available in the input.

Clinical Context

A 58-year-old patient with metastatic colorectal cancer undergoes molecular testing to guide targeted therapy selection. The treating oncologist orders a specialized next-generation sequencing assay to evaluate uncommon gene rearrangements and rare variants not covered by existing specific CPT codes. A blood specimen (liquid biopsy) or formalin-fixed paraffin-embedded tumor tissue is collected in the outpatient oncology clinic. The specimen is sent to a molecular pathology reference laboratory where nucleic acid extraction, library preparation, sequencing, and bioinformatic analysis are performed. Results identifying actionable variants are routed back to the oncologist, who integrates findings into treatment planning. Billing uses 81479 to report the molecular pathology procedure because no specific CPT code exists for the exact combination of methods or targets performed.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	When billing separately for the physician's interpretation of the molecular test distinct from the laboratory technical component.
`TC`	Technical component

Taxonomy Code	Specialty	Notes
207RH0000X	Hematology & Oncology	Oncologists who order and interpret molecular testing for cancer therapy planning.
2085P0207X	Molecular Pathology	Pathology subspecialists directing molecular laboratory operations and interpretations.
207L00000X	Pathology	Anatomic and clinical pathologists involved in specimen handling and diagnosis.
362L00000X	Clinical Laboratory Director	Laboratory directors overseeing testing quality and reporting.
207K00000X	Internal Medicine	Internists who may order molecular testing for complex diagnostic problems.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C18.9`	Malignant neoplasm of colon, unspecified	Common indication for comprehensive molecular profiling to identify actionable mutations for targeted therapy.
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Metastatic disease often triggers expanded molecular testing to guide systemic treatment.
`C50.912`	Malignant neoplasm of unspecified site of left female breast	Breast cancer specimens frequently undergo molecular assays when specific actionable variants are suspected.
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Lung cancers routinely require molecular testing for driver mutations when specific codes may not apply.
`Z85.3`	Personal history of malignant neoplasm of breast	History of cancer may prompt repeat or specialized molecular testing for recurrence or therapy selection.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`88305`	Level IV surgical pathology, gross and microscopic examination	May be billed when tissue is processed and reviewed histologically before or alongside molecular testing.
`81445`	Oncology (lung, colon, or other) hot-spot panel, targeted sequence analysis	Performed when a defined panel exists; `81479` is used when the exact assay does not have a specific panel code.
`81443`	Molecular pathology procedure, level 3 (eg, common single gene analysis)	Used for single-gene tests; `81479` covers assays without a precise code or novel multi-gene approaches.
`81162`	Interpretation and report of sequence analysis; mitochondrial genome, whole genome	Related for reporting complex genomic sequence analyses; billing depends on test specifics and whether a specific CPT exists.
`0000U`	Proprietary laboratory analyses (example PLA codes)	Proprietary/PLA codes are alternative specific codes; when none apply, `81479` is reported.

OpenPayer

Summary & Overview

CPT 81479: Unlisted Molecular Pathology Procedure